Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.
Introduction
Reticulin fibres are a physiological component of bone marrow stroma, and can be appreciated as a loose meshwork in histological sections stained with silver impregnation. Several reactive and neoplastic conditions elicit an increase of the normal meshwork, and an advanced degree of reticulin fibrosis is often accompanied by other stromal changes, such as collagen deposition, osteosclerosis and microvessel proliferation. These changes are not found physiologically in the bone marrow, with the exception of sporadic perivascular collagen fibres. The pathogenesis of bone marrow stromal changes is unclear, but evidence suggests that reticulin fibrosis and collagen deposition may differ in terms of reversibility and clinical implications. 1, 2 Attempts to estimate the grade of bone marrow fibrosis have been carried out since the first grading system in 1971. 3 The 2005 European Consensus on Grading of Bone Marrow Fibrosis (ECGMF), 4 included in the 2008 World Health Organisation (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues 5 and confirmed, with minor changes, in the 2016 update of the WHO classification, 6 is the current grading system for bone marrow fibrosis. It focuses mainly on reticulin fibrosis, while collagen deposition and osteosclerosis are not evaluated separately, and lack a well-established grading system.
The grade of bone marrow fibrosis according to ECGMF (ECGMF grade) bears clinical implications, especially in myeloid neoplasms. It has predictive value on response to therapy and outcome in BCR-ABL1-positive chronic myeloid leukaemia, 7 and correlates with transfusion requirement and prognosis in myelodysplastic syndromes. 8, 9 Among BCR-ABL1-negative myeloproliferative neoplasms (MPNs), cases of polycythaemia vera with an initial grade of bone marrow fibrosis (MF-1) show an inferior myelofibrosis-free survival, while advanced fibrosis (MF-2 or MF-3) is associated more frequently with a complex karyotype. 10, 11 In primary myelofibrosis (PMF), the ECGMF grade is associated with relevant haematological findings, and its prognostic role is proved in comparison with other prognostic scoring systems. 12, 13 Moreover, a more accurate stratification of PMF patients is achieved when considering the ECGMF grade along with International Prognostic Scoring System (IPSS) risk categories. 14 Patients with a high ECGMF grade (MF-2 or MF-3) display features indicative of an advanced disease, such as anaemia, leukopenia, thrombocytopenia, constitutional symptoms, larger splenomegaly and high IPSS risk categories. They are also more likely to have additional somatic mutations in ASXL1 and EZH2 genes, which are connected to adverse prognosis, and tend to have a significant reduction of overall survival when compared to early PMF patients. 15 Other stromal changes such as collagen deposition and osteosclerosis are gaining attention, especially in the context of Janus kinase (JAK) inhibitors therapy [16] [17] [18] [19] [20] [21] [22] [23] and haematopoietic stem cell transplantation (HSCT). 24 Therefore, a careful histological examination is crucial for PMF patients, both at the first biopsy and during follow-up. A new grading system of bone marrow stromal changes has been proposed recently by Kvasnicka et al., and proved to be reproducible. It evaluates reticulin fibrosis, collagen deposition and osteosclerosis separately, with specific recommendations to improve the staining quality and laboratory standards. 25 In this study, we hypothesize that a comprehensive assessment of reticulin fibrosis, collagen deposition and osteosclerosis may have prognostic implication and allow a better stratification of PMF patients. To verify the hypothesis, reticulin fibrosis, collagen deposition and osteosclerosis were first evaluated separately, according to the grading system proposed by Kvasnicka et al. 25 Then, for each case, the evaluated stromal changes were summarized in a comprehensive score [reticulin, collagen, osteosclerosis (RCO) score]. Finally, the results obtained with RCO score were compared to those obtained with ECGMF grade and IPSS risk categories.
Materials and methods

P A T I E N T S
The study involved 122 consecutive PMF patients diagnosed between 1998 and 2015 (median followup: 4.7 years, range: 1.4 months-13.6 years) at the Hematology Division of the Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico of Milan. Inclusion criteria were the trephine biopsy length (more than 1 cm) and the availability of complete clinical history, laboratory and follow-up data, and the patient's informed consent. All cases met the 2008 WHO criteria for PMF, and biopsies were performed at baseline observation: in particular, no patient received prior cytoreductive therapy.
The cases were reviewed by two experienced pathologists (U.G., S.F.) and classified, according to the 2016 updated WHO criteria, as prePMF and overt PMF.
B O N E M A R R O W E V A L U A T I O N
Formalin-fixed, paraffin-embedded bone marrow trephine biopsies were cut at 5-lm intervals and the resulting sections were stained with haematoxylin and eosin (H&E), Giemsa, Gomori's silver impregnation and Masson's trichrome. The grade of bone marrow stromal changes was assessed according to the new grading system. 25 We decided not to evaluate microvessel proliferation, another stromal alteration that occurs along with the increase of bone marrow fibrosis, 26 as it lacks a well-established grading system. Perivascular reticulin and collagen fibres were considered as internal quality controls, and fibre density was evaluated only in haematopoietic areas. In the case of heterogeneous patterns, the final grade was considered the highest in at least 30% of bone marrow area.
Reticulin fibrosis was evaluated on Gomori's silver impregnation stained slides and scored as: MF-0, scattered linear reticulin with no intersections (cross-overs), corresponding to normal bone marrow; MF-1, loose network of reticulin with many intersections, especially in perivascular areas; MF-2, diffuse and dense increase in reticulin with extensive intersections, occasionally with focal bundles of thick fibres mainly consistent with collagen and/or focal osteosclerosis; MF-3, diffuse and dense increase in reticulin with extensive intersections and coarse bundles of thick fibres mainly consistent with collagen, usually associated with osteosclerosis. Collagen deposition was evaluated on Masson's trichromestained slides and scored as: Co-0, perivascular collagen only (normal); Co-1, focal paratrabecular and/or central collagen deposition without connecting meshwork; Co-2, paratrabecular and/or central deposition of collagen with focally connecting meshwork or generalized paratrabecular apposition of collagen; and Co-3, diffuse (complete) connecting meshwork of collagen. Osteosclerosis was evaluated on H&E-stained slides and scored as: Ost-0, regular bone trabeculae (distinct paratrabecular borders); Ost-1, focal budding, hooks, spikes or paratrabecular apposition of new bone; Ost-2, diffuse paratrabecular new bone formation with thickening of trabeculae, occasionally with focal interconnections; and Ost-3, extensive interconnecting meshwork of new bone with overall effacement of marrow spaces. Examples of the evaluated morphological changes are reported in Figure 1 .
A comprehensive score (RCO score), obtained by summing the grade of each morphological parameter (grade of reticulin fibrosis + grade of collagen deposition + grade of osteosclerosis), ranging from 0 to 9, was assigned to each case. To simplify clinical applicability, the cases were divided into two groups: RCO low-grade (RCO score ranging from 0 to 4) and RCO high-grade (RCO score ranging from 5 to 9). We chose to set a cut-off of 5 for RCO high-grade cases because it implied, in our series, at least two highgrade (grades 2 or 3) stromal changes.
S T A T I S T I C A L A N A L Y S I S
Continuous variables were expressed as median and range and categorical variables as absolute frequency and percentage. A logistic model was used to assess association between covariates and mortality. Kaplan-Meier survival analysis was used to evaluate different groups of ECGMF grade, RCO score and IPSS in relation to time.
Statistical significance was set at a level of P < 0.05. Sidak correction was used for multiple testing. Given m different null hypotheses and a familywise a of 0.05, each null hypothesis with a P-value lower than 1 À (1 À a)
1/m was rejected. Data processing and all the statistical analyses were performed using SAS software version 9.2 (SAS Institute, Cary, NC, USA).
Results
B A S E L I N E C H A R A C T E R I S T I C S O F T H E P A T I E N T S
The study involved a consecutive series of 122 PMF patients diagnosed according to the 2008 WHO criteria and revised according to the 2016 update of WHO classification; 69 (57%) were revised as prePMF (ECGMF grade: MF-0 or MF-1) and 53 (43%) as overt PMF (ECGMF grade: MF-2 or MF-3).
The series included 56 males and 66 females (M/F = 85%), with a median age at diagnosis of 68 years (range: 30-85). Anaemia (haemoglobin <10 g/ dl) was found in 20 patients (16%), leucocytosis (leucocytes >25 9 10 9 /l) in four patients (3%) and thrombocytopenia (platelets <100 9 10 9 /l) in seven patients (6%). The main clinical data are summarized in Table 1 .
JAK2V617F mutation was detected in 81 cases (66%). Among the remaining 41, three carried the MPLW515L mutation, one the MPLW515R and 27 a mutation in exon 9 of the calreticulin (CALR) gene. In the latter group, 15 cases showed a type 1 mutation (del52bp), nine a type 2 mutation (ins5bp) and three other variants (del4bp, del19bp and del5ins12bp). The remaining 10 patients were 'triple-negative' (i.e. with no JAK2, CALR or MPL mutations).
According to IPSS, 38 cases were stratified as low risk, 51 as intermediate-1 risk, 21 as intermediate-2 risk and 12 as high risk.
By the time of the analysis, 21 patients (17%) had died; leukaemic evolution occurred in 14 patients (11.5%) and thrombo-haemorrhagic events in 25 (20.5%).
The histological analysis of bone marrow stromal changes, according to the grading system proposed by Kvasnicka et al., 25 gave the following results: reticulin fibrosis, MF-0 = 9, MF-1 = 60, MF-2 = 31 and MF-3 = 22; collagen deposition, Co-0 = 64, Co-1 = 23, Co-2 = 21 and Co-3 = 14; and osteosclerosis, Ost-0 = 72, Ost-1 = 24, Ost-2 = 19 and Ost-3 = 7. Stromal changes evolved harmonically for the three morphological features, with few exceptions. Four of 60 cases with MF-1 reticulin fibrosis displayed Ost-2 osteosclerosis (7%) (Figure 2 ). Moreover, of 31 cases with MF-2 reticulin fibrosis, two were associated with a Co-3 collagen deposition and seven with a Ost-2 osteosclerosis. The details of stromal changes evaluation are listed in Table 2 .
Mortality, as a dependent variable in a logistic model, was associated with the grade of reticulin A comprehensive score (RCO score), obtained by summing the grade of each morphological parameter (grade of reticulin fibrosis + grade of collagen deposition + grade of osteosclerosis), thus ranging from 0 to 9, was assigned to each case.
RCO score 1 was the most frequent in our series: it was found in 51 patients (41.8%), 50 of whom showed a MF-1/Co-0/Ost-0 combination. RCO score 4 was the second most frequent and found in 14 patients (11.4%). It was ascribable to a MF-2/Co-1/ Ost-1 combination in 11 of 14 patients (78.5%). RCO scores and individual grades of reticulin fibrosis, collagen deposition and osteosclerosis are reported in Table 3 .
P R O G N O S T I C S I G N I F I C A N C E O F R C O S C O R E
To simplify the clinical applicability, we divided the patients in two groups, according to their RCO score: RCO low-grade (RCO score 0-4) and RCO high-grade (RCO score 5-9). Eighty-eight (72%) of 122 patients were placed in the RCO low-grade group and 34 (28%) in the RCO high-grade group.
Patients in the RCO high-grade group displayed laboratory features indicative of an advanced disease: they had a higher percentage of anaemia, thrombocytopenia, leucocytosis, peripheral blood blasts and increased lactate dehydrogenase (LDH) levels. The clinical features according to RCO grade group are summarized in Table 4 . RCO scores were associated strictly (P < 0.001) with IPSS risk categories and overall survival (RCO low-grade: 10 dead patients of 88 versus RCO highgrade: 11 dead patients of 34; P = 0.0059). Conversely, it was not associated with the percentage of leukaemic transformation (P = 0.18) or thrombo-haemorrhagic events (P = 0.76).
RCO score was able to discriminate the overall survival (OS) of patients: the 75th percentile OS in the RCO score low-grade group was 12.5 years, against 3.5 years in the RCO score high-grade group (logrank test: P < 0.001).
We compared the OS curves obtained with RCO score to those obtained with ECGMF grade: RCO score were more accurate in identifying high-risk patients with poor prognosis ( Figure 3A) . The RCO low-grade group included 11 overt PMF patients (MF-2) with RCO score 4. These patients did not seem to differ in terms of OS when compared to prePMF (MF-0 or MF-1) RCO low-grade patients ( Figure 3A) . We compared clinical and pathological features of prePMF and overt PMF patients in the RCO low-grade group. As seen in Table 5 , no significant difference was found. Hb level <10 g/dl, no. of patients (%) 5 (7) 2 ( We matched the OS curves obtained with RCO score to those obtained with IPSS risk categories: the two systems showed comparable results, even if IPSS was slightly more effective in differentiating high-risk patients after 60 months of follow-up ( Figure 3B) .
We then investigated if a combined evaluation of RCO score and IPSS risk categories could allow a more accurate stratification. For this purpose, each patient was assigned to a further risk subgroup, created by an integrated estimation of IPSS risk categories and RCO score: low-risk (IPSS low/ intermediate-1 risk + RCO low-grade), moderate-risk (IPSS intermediate-2/high-risk + RCO low-grade or IPSS low/intermediate-1 risk + RCO high-grade) and high-risk (IPSS intermediate-2/high risk + RCO highgrade). RCO score added prognostic information to the IPSS risk categories: in fact, the combined evaluation was more accurate than IPSS alone. For instance, the median survival of intermediate-2/highrisk IPSS patients declined from 9.7 to 4.9 years if a high-grade RCO score was associated. A significant difference was also found in OS curves obtained with RCO score and IPSS together (P < 0.001). These results are summarized in Figure 3C .
The combined evaluation provided an increase in positive predictive value (PPV) for mortality in the high-risk group: PPV raised from 32% (when considering RCO score alone) and 36% (when considering IPSS alone) to 42% when considering RCO score and IPSS together. The results are listed in Table 6 .
Finally, we compared OS curves resulting from two different combined analyses: IPSS + RCO score versus IPSS + ECGMF grade. The former combination was more accurate in discriminating the OS of high-risk patients, especially after 60 months of follow-up (Figure 3D ).
Discussion
We hypothesized that a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis, according to the grading system proposed by Kvasnicka et al., 25 may have prognostic implication and may allow a more effective stratification of PMF patients.
To verify the hypothesis, we assessed reticulin fibrosis, collagen deposition and osteosclerosis in baseline bone marrow trephine biopsies of 122 consecutive PMF patients, assigning a grade from 0 to 3 to each parameter. A comprehensive score (RCO score, obtained by summing the individual grade of reticulin fibrosis, collagen deposition and osteosclerosis) for each case enabled us to identify two groups of patients characterized by low-grade (RCO score 0-4) and high-grade (RCO score 5-9) bone marrow stromal changes, and by different clinical features. In fact, patients in the RCO high-grade group displayed more frequently laboratory features indicative of advanced disease, such as anaemia, thrombocytopenia, peripheral blood blasts and increased LDH levels.
RCO score was associated strictly with OS and IPSS risk categories. OS curves according to RCO score were significantly different for low-and high-grade groups: the 75th percentile value of 12.5 years for RCO low-grade patients decreased to 3.5 years for RCO high-grade patients. Moreover, RCO score proved to be more accurate than the current grading system, based on the ECGMF grade, in identifying high-risk patients with poor prognosis. Interestingly, the subset of RCO low-grade patients with overt PMF (ECGMF grade MF-2), according to the 2016 update of WHO classification, displayed an OS curve comparable to RCO low-grade patients with prePMF (ECGMF grades MF-0 or MF-1), and did not show any significant clinical and pathological differences. This finding supports further the value of a comprehensive histological evaluation of bone marrow stromal changes in stratifying PMF patients.
Finally, a combined assessment of RCO score and IPSS risk categories increased PPV for mortality. In fact, for high-risk patients (RCO high-grade and IPSS intermediate-2/high risk), PPV rose from 32% (when considering RCO score alone) and 36% (when considering IPSS alone) to 42% when considering RCO score and IPSS together. This means that the application of the RCO along with the IPSS risk category allows a more effective stratification of PMF patients.
To our knowledge, this is the first study that specifically investigates the prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in a series of PMF patients.
The ECGMF grade is known to play a major prognostic role in PMF patients. For example, when our group examined the prognostic significance of ECGMF grade in PMF patients and its relationship with IPSS risk categories, 13,14 the two systems were able to predict survival independently at a multivariate analysis. Additionally, a more accurate prognostication was achieved when the two systems were used together. More recently, a work by Guglielmelli et al. 15 on a large series of PMF patients confirmed our results, disclosing that a high ECGMF grade (MF-2 or MF-3) is associated with cytopenias, circulating blasts, larger splenomegaly and a higher IPSS risk category. These patients were also enriched in prognostically unfavourable mutations, in particular ASXL1 and EZH2. These data suggest that a high ECGMF grade represents an adverse prognostic factor, and that it can provide supplementary information in lower IPSS risk categories, a group of patients where clear indications for treatment are still missing.
Other stromal changes, such as collagen deposition and osteosclerosis, remained under-recognized, although found commonly in association with advanced bone marrow fibrosis in BCR-ABL1-negative MPNs. 27, 28 A grading system for reticulin fibrosis, collagen deposition and osteosclerosis was proposed recently by Kvasnicka et al. 25 It proved to be reproducible in a multicentre study that involved 11 haematopathologists in a blinded assessment. The overall inter-rater reliability ranged between 0.898 and 0.926 for all three parameters analysed (reticulin fibrosis, collagen deposition and osteosclerosis). An additional issue from that work concerned the identification of specific problems and pitfalls in the interpretation of each single morphological parameter (for instance, biopsy length, presence of crushing artefacts and squeezing, thickness of sections and quality of staining).
Collagen deposition and osteosclerosis are gaining attention as indicators of therapy response in the background of JAK inhibitor treatment and HSCT. In fact, a stabilization or regression of reticulin fibrosis, collagen deposition and osteosclerosis is described after prolonged therapy with JAK inhibitors. [18] [19] [20] [21] [22] [23] While a prompt reduction in reticulin fibrosis is also reported after HSCT, the complete regression of collagen deposition or osteosclerosis is unclear. 24 Hence, a reproducible grading system for collagen deposition and osteosclerosis is necessary for the supervision of response to therapy in these patients.
In conclusion, our study shows that the histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in a comprehensive RCO score is prognostically significant, more accurate than ECGMF grade in identifying high-risk patients with poor prognosis and improves PPV for mortality when applied in addition to IPSS risk categories. However, two important limitations of our study consist in its retrospective nature and the relatively low number of examined patients and clinical events. For this reason, prospective studies with a larger number of patients are needed to confirm the prognostic value of the RCO score to evaluate its relationship with the presence of adverse somatic mutations, such as ASXL1 and EZH2, and its relevance in management of PMF patients at diagnosis and after therapy.
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